Evidence map›Paper›PMID 27796709›Full record

ArticlePituitary2017

Effects of somatostatin and its analogues on progenitor mesenchymal cells isolated from human pituitary adenomas.

Monia Orciani, Miriam Caffarini, Giulia Sorgentoni, Riccardo Antonio Ricciuti, Giorgio Arnaldi, Roberto Di Primio

Abstract read
PubMed Publisher
In one paragraph

Article in Pituitary, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Identification and Interaction Analysis of Molecular Markers in Colorectal Cancer by Integrated Bioinformatics Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Article
  7. Pituitary adenomas, stem cells, and cancer stem cells: what's new?Journal of endocrinological investigation · 2018
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Monia OrcianiDepartment of Clinical and Molecular Sciences - Histology, Università Politecnica delle Marche, Via Tronto 10/A, 60126, Ancona, Italy. m.orciani@univpm.it.
Miriam CaffariniDepartment of Clinical and Molecular Sciences - Histology, Università Politecnica delle Marche, Via Tronto 10/A, 60126, Ancona, Italy.
Giulia SorgentoniDepartment of Clinical and Molecular Sciences - Histology, Università Politecnica delle Marche, Via Tronto 10/A, 60126, Ancona, Italy.
Riccardo Antonio RicciutiDepartment of Neurological, Medical and Surgery Sciences, Azienda Ospedali Riuniti di Ancona, Via Conca, 60126, Ancona, Italy.
Giorgio ArnaldiDepartment of Clinical and Molecular Sciences - Endocrinology, Università Politecnica delle Marche, Via Tronto 10/A, 60126, Ancona, Italy.
Roberto Di PrimioDepartment of Clinical and Molecular Sciences - Histology, Università Politecnica delle Marche, Via Tronto 10/A, 60126, Ancona, Italy.
Marche Polytechnic University · ITOspedali Riuniti di Ancona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeProgenitor mesenchymal cells (PMCs) have been found also in epithelial tumors and may derive from cancer stem cells (CSCs) by EMT mechanism. In this scenario, the effects of traditionally drugs on PMCs become of primary concern for therapeutic approaches. Previously, we isolated PMCs from acromegalic (GHomas) and not-functioning pituitary adenomas (NFPAs). Here we evaluate: (1) the role of EMT on their origin; (2) the presence of the somatostatin receptors (SSTR1-5); (3) the effects of somatostatin (SST) and its analogues (SSAs) on PMCs proliferation, apoptosis and SSTR1-5 expression.

methodsPMCs were isolated from GHomas and NFPAs; the expression of E-CADHERIN and TGFβRII (referred to EMT), the expression of the SSTR1-5 as well as the proliferation and apoptosis were tested before and after drugs administration.

resultsResults show a decrease of E-CADHERIN and an increase of TGFβRII, confirming an EMT involvement; SSTR1-5 are more expressed by PMCs from GHomas than from NFPAs. SST and SSAs administration does not affect cell proliferation and SSTR1-5 expression on PMCs from NFPAs while in PMCs from GHomas, cell proliferation showed a marked decrease and a corresponding increase in the expression of SSTR1-2. Apoptosis rate and EMT were not affected by drugs administration.

conclusionsResults indicate as EMT may be related to the presence of PMCs on pituitary tumors; SSAs, currently used in the management of human GHomas, exert anti-proliferative effect also in PMCs that, because of their derivation from CSCs, may be a new meaningful target for drugs treatment.

Indexed as

AcromegalyCell ProliferationCells, CulturedEpithelial-Mesenchymal TransitionHumansNeoplastic Stem CellsPituitary NeoplasmsSomatostatinStem CellsSomatostatinEpithelial–mesenchymal-transitionPituitary adenomasProgenitor cellsSomatostatin analogues

Identifiers

PMID27796709
OpenAlexW2546183493

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.